GRAL
GRAL
NASDAQ · Biotechnology

Grail Inc

$62.10
-1.64 (-2.57%)
Analyst Consensus
Buy
14
Analysts
Moderate
Coverage
Buy 9 64%
Hold 5 36%
Sell 0 0%
Price Target
Analyst Price Target -45.9% upside
Low Target $28.45
Average Target $33.59
High Target $56.21
Current Price $62.10
Current
$62.10
Target
$33.59
$28.45 $33.59 avg $56.21
Scenario Analysis
Bear Case
$28.45
-54.2%
Low target
Base Case
$33.59
-45.9%
Avg target
Bull Case
$56.21
+-9.5%
High target
Risk/Reward
0.2x
Unfavorable
Price in Context
52-Week High
$118.84
-47.7% from high
52-Week Low
$29.95
+107.3% from low
50-Day SMA
$97.75
-36.5% vs SMA
200-Day SMA
$64.49
-3.7% vs SMA
RSI (14)
50.6
Neutral
Target vs 52W High
$33.59
-71.7% vs high
Peer Consensus — Biotechnology
Stock Consensus Analysts Buy % Target Upside
ABBV
Abbvie Inc
Strong Buy 40 78% $257.58 +12.0%
AMGN
Amgen Inc
Hold 44 50% $190.87 -44.6%
GILD
Gilead Sciences Inc
Strong Buy 39 82% $362.68 +190.4%
VRTX
Vertex Pharmaceuticals Inc
Strong Buy 40 83% $438.34 -6.1%
REGN
Regeneron Pharmaceuticals
Buy 38 71% $76.80 -87.5%
ALNY
Alnylam Pharmaceuticals Inc
Strong Buy 37 76% $102.31 -64.3%
RVMD
Revolution Medicines Inc
Strong Buy 27 96% $114.11 -31.2%
NTRA
Natera Inc
Strong Buy 27 89% $142.91 -37.5%